Supplementary Figure 5 from An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

crossref(2023)

Cited 0|Views15
No score
Abstract

PDF file - 237K, Figure S5. Combination treatment consisting of trastuzumab+LJM716 or Cetuximab+LJM716 is well tolerated.

More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined